We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A 6-month Study to Evaluate Sulforaphane Effects in PD Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05084365
Recruitment Status : Not yet recruiting
First Posted : October 19, 2021
Last Update Posted : October 19, 2021
Sponsor:
Information provided by (Responsible Party):
Renrong Wu,PhD, Central South University

Brief Summary:
Parkinson's disease (PD) is a second common neurodegenerative disease. More than 6 million individuals worldwide have Parkinson disease. No disease-modifying pharmacologic treatments are available. Current medical treatment is symptomatic, focused on improvement in motor (eg, tremor, rigidity, bradykinesia) and nonmotor (eg, constipation, cognition, mood, sleep) signs and symptoms. Accumulating evidence suggests the important role for inflammation and oxidative stress in the pathogenesis of PD. Sulforaphane extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. Previous studies suggested sulforaphane is useful in dopaminergic neuron survival. In this study, the investigator attempts to evaluate the efficacy and safety of sulforaphane in PD patients.

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: Sulforaphane Drug: Placebo Phase 2

Detailed Description:
The study will recruit 100 PD patients, and then these patients will be randomized to sulforaphane group or placebo group (50 patients per arm) for 24 weeks clinic trial. Participants will receive 24 weeks of either sulforaphane or placebo per day, in addition to the existing treatment. Baseline assessments include demographics, a comprehensive medical history, anthropometric measurements (weight and height), physical examination, and lab work. The motor symptoms and cognitive function will be assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) and MATRICS Consensus Cognitive Battery #MCCB#, respectively, at baseline, week 12 and week 24. The cranial MRI is examined at baseline and repeated at week 24. The primary outcomes will be the cognitive function improvement. Secondary outcomes include motor symptoms, biological data, MRI, safety and tolerability. During the study period, safety index including blood routine, liver and kidney function and adverse reactions report will be recorded.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 6-month Study to Evaluate Sulforaphane Effects in Treatment of Cognition Impairment of PD Patients
Estimated Study Start Date : October 10, 2021
Estimated Primary Completion Date : October 1, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: sulforaphane
The goal of the study is to investigate whether adding sulforaphane will benefit cognitive function in individuals who have PD.
Drug: Sulforaphane
Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.

Placebo Comparator: placebo
The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
Drug: Placebo
Placebo




Primary Outcome Measures :
  1. Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score [ Time Frame: 24 weeks ]
    The investigators will use the MATRICS Consensus Cognitive Battery (MCCB) Composite score as primary cognitive outcome measure

  2. Change of clinical symptoms by UPDRS [ Time Frame: 24 weeks ]
    The change of UPDRS at different follow up point



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age range from 40 to 75, regardless of ethnic group or gender;
  2. Meeting the criteria for clinically established PD (2015) by Movement Disorder Association(MDS); duration < 5 years;
  3. Hoehn-Yahr stage ≤ 3;
  4. Before enrollment, patients should take a stable dose of dopamine-based therapies drugs;
  5. No obvious visual or hearing impairment;
  6. More than 9 years of education;
  7. Patients understand and comply with the study procedure, and are able to complete all tests and examinations required by the program. Sign the informed consent.

Exclusion Criteria:

  1. The total score of Mini-Mental State Examination (MMSE) ≤ 25 points;
  2. Patients who have received globus pallidotomy, thalamotomy, deep brain stimulation (DBS), or stem cell therapy;
  3. Other causes of parkinsonism: medications (e.g., metoclopramide, flunarizine), metabolic neurogenetic disorders (e.g., Wilson's disease), encephalitis, cerebrovascular diseases, or degenerative disorders (e.g., progressive supranuclear palsy);
  4. Central nervous system diseases (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy, etc.);
  5. Have liver, kidney function insufficiency;
  6. Unstable or severe diseases of the heart, lung, liver, kidney and hematopoietic system according to the judgment of the researchers;
  7. Participated in other clinical trials within 3 months before screening visit;
  8. Other conditions are unsuitable for participating in this study according to the judgement of researchers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05084365


Contacts
Layout table for location contacts
Contact: Renrong Wu +8615874179855 wurenrong@csu.edu.cn
Contact: Hainan Zhang +8613508474343 yyzhn@sina.com

Sponsors and Collaborators
Central South University
Layout table for additonal information
Responsible Party: Renrong Wu,PhD, Professor, Central South University
ClinicalTrials.gov Identifier: NCT05084365    
Other Study ID Numbers: PD-Sulforaphane
First Posted: October 19, 2021    Key Record Dates
Last Update Posted: October 19, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Renrong Wu,PhD, Central South University:
Sulforaphane
Parkinson's disease
cognition
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases
Sulforaphane
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents